Meeting NewsVideo

VIDEO: Initial results of ZUMA-3 trial ‘highly encouraging’ for relapsed, refractory leukemia

CHICAGO — Bijal D. Shah, MD, associate professor in the department of malignant hematology at Moffitt Cancer Center, spoke with HemOnc Today at ASCO Annual Meeting about the ZUMA-3 study.

The phase 1/phase 2 study evaluated KTE-X19 (Kite Pharma), an investigational anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed/refractory acute lymphoblastic leukemia.

Shah provided an overview of end-of-phase-1 results.

“We were able to identify a cell dose and a toxicity management algorithm that seems to come with highly encouraging response rates and highly encouraging durable remissions in an otherwise very heavily pretreated population,” Shah told HemOnc Today. “We’re really excited as we move this into phase 2. ... Hopefully we’ll have some exciting news to share in the near future.” – by Mark Leiser

Reference:

Shah BD, et al. Abstract 7006. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.

Disclosure: Shah reports honoraria from Pharmacyclics/Janssen, a consultant/advisory role with Adaptive Biotechnologies, and research funding from Incyte and Jazz Pharmaceuticals (institutional).

CHICAGO — Bijal D. Shah, MD, associate professor in the department of malignant hematology at Moffitt Cancer Center, spoke with HemOnc Today at ASCO Annual Meeting about the ZUMA-3 study.

The phase 1/phase 2 study evaluated KTE-X19 (Kite Pharma), an investigational anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed/refractory acute lymphoblastic leukemia.

Shah provided an overview of end-of-phase-1 results.

“We were able to identify a cell dose and a toxicity management algorithm that seems to come with highly encouraging response rates and highly encouraging durable remissions in an otherwise very heavily pretreated population,” Shah told HemOnc Today. “We’re really excited as we move this into phase 2. ... Hopefully we’ll have some exciting news to share in the near future.” – by Mark Leiser

Reference:

Shah BD, et al. Abstract 7006. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.

Disclosure: Shah reports honoraria from Pharmacyclics/Janssen, a consultant/advisory role with Adaptive Biotechnologies, and research funding from Incyte and Jazz Pharmaceuticals (institutional).

    See more from ASCO Annual Meeting